---
document_datetime: 2025-12-02 06:39:57
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/fiasp.html
document_name: fiasp.html
version: success
processing_time: 0.1187128
conversion_datetime: 2025-12-27 23:16:27.158622
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Fiasp

[RSS](/en/individual-human-medicine.xml/67064)

##### Authorised

This medicine is authorised for use in the European Union

insulin aspart Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Fiasp](#news-on)
- [Preventing medication errors](#preventing-medication-errors-1526)
- [Related information](#related-information-863)
- [More information on Fiasp](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Fiasp is a medicine that is used to treat children from one year of age and adults with diabetes. It contains the active substance insulin aspart, a rapid-acting insulin.

Expand section

Collapse section

## How is Fiasp used?

Fiasp is a solution for injection available in vials, cartridges or pre-filled pens and can only be obtained with a prescription. It is usually injected under the skin of the belly or upper arm immediately before a meal, although it may be given up to 20 minutes after starting a meal if necessary. The dose depends on the patient's blood glucose, which should be tested regularly to find the dose that gives good control of blood sugar. When injected under the skin, Fiasp should be used in combination with an intermediate- or long-acting insulin that is given at least once a day.

Fiasp can also be used in a pump system for continuous insulin infusion under the skin or alternatively, it can be injected into a vein but only by a doctor or a nurse.

For more information about using Fiasp, see the package leaflet or contact your doctor or pharmacist.

## How does Fiasp work?

Diabetes is a disease in which blood glucose is high, either because the body cannot produce insulin (type 1 diabetes) or because the body does not make enough insulin or cannot use it effectively (type 2 diabetes). The replacement insulin in Fiasp acts in the same way as the body's own insulin and helps glucose enter cells from the blood. This controls the level of blood glucose and reduces the symptoms and complications of diabetes. Insulin aspart enters the bloodstream faster than human insulin after injection and therefore works more quickly.

## What benefits of Fiasp have been shown in studies?

The benefits of Fiasp in reducing blood glucose as part of diabetes treatment have been shown in 4 main studies.

In two studies Fiasp was at least as effective as another insulin, NovoRapid. Both Fiasp and NovoRapid contain insulin aspart but Fiasp contains some different ingredients intended to help it to be absorbed rapidly. The main measure of effectiveness was the medicine's ability to decrease the level in the blood of glycosylated haemoglobin (HbA1c), a substance which indicates how well blood glucose is controlled over time. One study involving 1,143 adults with type 1 diabetes whose starting HbA1c was around 7.6% found that after 6 months of treatment HbA1c fell by 0.32 percentage points with a mealtime dose of Fiasp, compared with 0.17 points with the other insulin. In the second study involving 689 adults with type 2 diabetes, the fall after 6 months of treatment (from a starting value of 7.96% and 7.89% respectively) was 1.38 points with Fiasp and 1.36 points with the comparator.

A third study involving 236 adults with type 2 diabetes and a starting HbA1c of around 7.9% found that adding mealtime Fiasp to treatment with a long-acting insulin and the diabetes medicine metformin improved blood glucose control. (There was no direct comparison between Fiasp and another mealtime insulin in this study.) In patients given Fiasp the HbA1c fell after 18 weeks by 1.16 percentage points, compared with 0.22 points in those on long-acting insulin and metformin alone.

A fourth study in 777 adolescents and children from 2 years of age with type 1 diabetes and a starting HbA1c of around 7.6% compared Fiasp (given at mealtime or 20 minutes after the start of the meal) with NovoRapid (given at mealtime). In this study, Fiasp was at least as effective as the comparator: there was almost no change in HbA1c in patients given Fiasp at mealtime (0.05 percentage points) and a similar slight increase in those given Fiasp after a meal or NovoRapid at mealtime (0.35 and 0.23 percentage points respectively).

## What are the risks associated with Fiasp?

The most common side effect with Fiasp (which may affect more than 1 in 10 people) is hypoglycaemia (excessively low blood sugar). Hypoglycaemia can occur more quickly with Fiasp than with other mealtime insulins. For the full list of side effects and restrictions of Fiasp, see the package leaflet.

## Why is Fiasp authorised in the EU?

A clinically relevant benefit in lowering blood glucose has been shown in studies with Fiasp.

Compared with the already authorised insulin aspart medicine NovoRapid, the lowering of blood glucose develops earlier in adults given Fiasp, although the total extent of the lowering effect is similar. However, it is unclear whether this changes the risk of diabetic complications. The overall rate and severity of side effects was comparable with NovoRapid, although hypoglycaemia occurred more often in the first 2 hours after a dose of Fiasp. The benefits of Fiasp were also shown in children. Although Fiasp was not studied in children below 2 years of age, it is also expected to have a beneficial effect in younger children. The slightly higher risk of hypoglycaemia at night in children treated with Fiasp is addressed in the product information and is considered manageable.

The European Medicines Agency therefore decided that Fiasp's benefits outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Fiasp?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fiasp have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Fiasp are continuously monitored. Side effects reported with Fiasp are carefully evaluated and any necessary action taken to protect patients.

## Other information about Fiasp

Fiasp received a marketing authorisation valid throughout the EU on 9 January 2017.

Fiasp : EPAR - Medicine overview

Reference Number: EMA/467722/2019

English (EN) (110.22 KB - PDF)

**First published:** 03/02/2017

**Last updated:** 26/08/2019

[View](/en/documents/overview/fiasp-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-987)

български (BG) (141.44 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/bg/documents/overview/fiasp-epar-medicine-overview_bg.pdf)

español (ES) (115.71 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/es/documents/overview/fiasp-epar-medicine-overview_es.pdf)

čeština (CS) (141.49 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/cs/documents/overview/fiasp-epar-medicine-overview_cs.pdf)

dansk (DA) (115.27 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/da/documents/overview/fiasp-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.48 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/de/documents/overview/fiasp-epar-medicine-overview_de.pdf)

eesti keel (ET) (103.89 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/et/documents/overview/fiasp-epar-medicine-overview_et.pdf)

ελληνικά (EL) (140.3 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/el/documents/overview/fiasp-epar-medicine-overview_el.pdf)

français (FR) (117.26 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/fr/documents/overview/fiasp-epar-medicine-overview_fr.pdf)

hrvatski (HR) (139.11 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/hr/documents/overview/fiasp-epar-medicine-overview_hr.pdf)

italiano (IT) (114.43 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/it/documents/overview/fiasp-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (154.63 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/lv/documents/overview/fiasp-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (137.76 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/lt/documents/overview/fiasp-epar-medicine-overview_lt.pdf)

magyar (HU) (138.52 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/hu/documents/overview/fiasp-epar-medicine-overview_hu.pdf)

Malti (MT) (140.65 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/mt/documents/overview/fiasp-epar-medicine-overview_mt.pdf)

Nederlands (NL) (116.4 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/nl/documents/overview/fiasp-epar-medicine-overview_nl.pdf)

polski (PL) (141.32 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/pl/documents/overview/fiasp-epar-medicine-overview_pl.pdf)

português (PT) (117.16 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/pt/documents/overview/fiasp-epar-medicine-overview_pt.pdf)

română (RO) (134.88 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/ro/documents/overview/fiasp-epar-medicine-overview_ro.pdf)

slovenčina (SK) (140.98 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/sk/documents/overview/fiasp-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.54 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/sl/documents/overview/fiasp-epar-medicine-overview_sl.pdf)

Suomi (FI) (113.68 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/fi/documents/overview/fiasp-epar-medicine-overview_fi.pdf)

svenska (SV) (114.13 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

26/08/2019

[View](/sv/documents/overview/fiasp-epar-medicine-overview_sv.pdf)

Fiasp : EPAR - Risk-management-plan summary

English (EN) (69.78 KB - PDF)

**First published:** 26/08/2019

**Last updated:** 15/06/2020

[View](/en/documents/rmp-summary/fiasp-epar-risk-management-plan-summary_en.pdf)

## Product information

Fiasp : EPAR - Product Information

English (EN) (1.03 MB - PDF)

**First published:** 03/02/2017

**Last updated:** 23/09/2021

[View](/en/documents/product-information/fiasp-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-728)

български (BG) (1.26 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/bg/documents/product-information/fiasp-epar-product-information_bg.pdf)

español (ES) (1.02 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/es/documents/product-information/fiasp-epar-product-information_es.pdf)

čeština (CS) (1.17 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/cs/documents/product-information/fiasp-epar-product-information_cs.pdf)

dansk (DA) (1.04 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/da/documents/product-information/fiasp-epar-product-information_da.pdf)

Deutsch (DE) (1.08 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/de/documents/product-information/fiasp-epar-product-information_de.pdf)

eesti keel (ET) (971.33 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/et/documents/product-information/fiasp-epar-product-information_et.pdf)

ελληνικά (EL) (1.27 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/el/documents/product-information/fiasp-epar-product-information_el.pdf)

français (FR) (1.06 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/fr/documents/product-information/fiasp-epar-product-information_fr.pdf)

hrvatski (HR) (1.26 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/hr/documents/product-information/fiasp-epar-product-information_hr.pdf)

íslenska (IS) (906.76 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/is/documents/product-information/fiasp-epar-product-information_is.pdf)

italiano (IT) (1.03 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/it/documents/product-information/fiasp-epar-product-information_it.pdf)

latviešu valoda (LV) (1.21 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/lv/documents/product-information/fiasp-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.12 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/lt/documents/product-information/fiasp-epar-product-information_lt.pdf)

magyar (HU) (1.13 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/hu/documents/product-information/fiasp-epar-product-information_hu.pdf)

Malti (MT) (1.27 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/mt/documents/product-information/fiasp-epar-product-information_mt.pdf)

Nederlands (NL) (1.02 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/nl/documents/product-information/fiasp-epar-product-information_nl.pdf)

norsk (NO) (1.01 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/04/2024

[View](/no/documents/product-information/fiasp-epar-product-information_no.pdf)

polski (PL) (1.22 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/pl/documents/product-information/fiasp-epar-product-information_pl.pdf)

português (PT) (1.04 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/pt/documents/product-information/fiasp-epar-product-information_pt.pdf)

română (RO) (1.26 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/ro/documents/product-information/fiasp-epar-product-information_ro.pdf)

slovenčina (SK) (1.17 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/sk/documents/product-information/fiasp-epar-product-information_sk.pdf)

slovenščina (SL) (1.1 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/sl/documents/product-information/fiasp-epar-product-information_sl.pdf)

Suomi (FI) (997.91 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

23/09/2021

[View](/fi/documents/product-information/fiasp-epar-product-information_fi.pdf)

svenska (SV) (1.03 MB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/04/2024

[View](/sv/documents/product-information/fiasp-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0028 18/08/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Fiasp : EPAR - All Authorised presentations

English (EN) (65.48 KB - PDF)

**First published:** 03/02/2017

**Last updated:** 15/06/2020

[View](/en/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-168)

български (BG) (79.81 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/bg/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_bg.pdf)

español (ES) (66.33 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/es/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_es.pdf)

čeština (CS) (79.37 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/cs/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (70.6 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/da/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (67.75 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/de/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (66.69 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/et/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (87.94 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/el/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_el.pdf)

français (FR) (66.83 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/fr/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (85.68 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/hr/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (69.45 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/is/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_is.pdf)

italiano (IT) (65.18 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/it/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (107.87 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/lv/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (87.99 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/lt/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (95.58 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/hu/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (84.1 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/mt/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (66.28 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/nl/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (68.43 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/no/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_no.pdf)

polski (PL) (111.66 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/pl/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_pl.pdf)

português (PT) (66.9 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/pt/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_pt.pdf)

română (RO) (101.85 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/ro/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (85.59 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/sk/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (84.02 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/sl/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (66.2 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/fi/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (68.9 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

15/06/2020

[View](/sv/documents/all-authorised-presentations/fiasp-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Fiasp Active substance insulin aspart International non-proprietary name (INN) or common name insulin aspart Therapeutic area (MeSH) Diabetes Mellitus Anatomical therapeutic chemical (ATC) code A10AB05

### Pharmacotherapeutic group

- Drugs used in diabetes
- Insulins and analogues for injection, fast-acting

### Therapeutic indication

Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

## Authorisation details

EMA product number EMEA/H/C/004046 Marketing authorisation holder

Novo Nordisk A/S

Novo Alle

Opinion adopted 10/11/2016 Marketing authorisation issued 09/01/2017 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Fiasp : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (187.59 KB - PDF)

**First published:** 27/04/2018

**Last updated:** 23/09/2021

[View](/en/documents/procedural-steps-after/fiasp-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Fiasp-H-C-4046-II-0010 : EPAR - Assessment report

Adopted

Reference Number: EMA/471389/2019

English (EN) (3.33 MB - PDF)

**First published:** 26/08/2019

[View](/en/documents/variation-report/fiasp-h-c-4046-ii-0010-epar-assessment-report_en.pdf)

Fiasp-H-C-PSUSA-00001749-201809 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/396551/2019

English (EN) (64.86 KB - PDF)

**First published:** 10/07/2019

[View](/en/documents/scientific-conclusion/fiasp-h-c-psusa-00001749-201809-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Fiasp (II/0010)

Adopted

Reference Number: EMA/CHMP/354045/2019

English (EN) (60.72 KB - PDF)

**First published:** 28/06/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fiasp-ii0010_en.pdf)

Fiasp-H-C-4046-P46-002 : EPAR - Assessment report

Adopted

Reference Number: EMA/142332/2019

English (EN) (2.32 MB - PDF)

**First published:** 26/02/2019

[View](/en/documents/variation-report/fiasp-h-c-4046-p46-002-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Fiasp : EPAR - Public assessment report

English (EN) (4.43 MB - PDF)

**First published:** 03/02/2017

**Last updated:** 03/02/2017

[View](/en/documents/assessment-report/fiasp-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Fiasp

Adopted

Reference Number: EMA/CHMP/702450/2016

English (EN) (73.48 KB - PDF)

**First published:** 11/11/2016

**Last updated:** 11/11/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-fiasp_en.pdf)

#### News on Fiasp

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019) 28/06/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 March 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-march-2018) 23/03/2018

[Colour change for insulin injection Fiasp to avoid mix ups with Tresiba](/en/news/colour-change-insulin-injection-fiasp-avoid-mix-ups-tresiba) 23/03/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2016) 11/11/2016

#### Preventing medication errors

Fiasp: colour change for insulin injection Fiasp to avoid mix ups with Tresiba

Reference Number: EMA/166410/2018

English (EN) (1.33 MB - PDF)

**First published:** 23/03/2018

**Last updated:** 23/03/2018

[View](/en/documents/medication-error/fiasp-colour-change-insulin-injection-fiasp-avoid-mix-ups-tresiba_en.pdf)

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0040460000) (initial marketing authorisation)

#### More information on Fiasp

- [Fiasp PumpCart (insulin aspart) - supply shortage](/en/medicines/human/shortages/fiasp-pumpcart-insulin-aspart)
- [Insulin (human insulin) (various short-, rapid-, intermediate-, mixed- and long-acting forms) - supply shortage](/en/medicines/human/shortages/insulin-human-insulin-various-short-rapid-intermediate-mixed-long-acting-forms)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 23/09/2021

## Share this page

[Back to top](#main-content)